**Supplementary Table S4.** characteristics of kidney transplant recipients with SARS-CoV-2 infection.

| Patient | Sex | Age | Primary kidney Disease | Pre-Existing Conditions | | | | | Induction Immunosuppression | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | HT | DM | COPD | CAD | BMI > 30 | Anti-IL2R Ab | rATG | MP | Anti-CD20 Ab | Anti-C5 Ab | PEX | IVIg |
| 1 | M | 54 | PUV | No | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 2 | F | 51 | Primary GN | Yes | Yes | No | No | No | No | Yes | Yes | No | No | Yes | Yes |
| 3 | M | 44 | ADPKD + Alport S. | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 4 | M | 61 | Primary GN | Yes | Yes | No | Yes | No | No | Yes | Yes | No | No | No | No |
| 5 | F | 52 | Primary GN | Yes | No | No | Yes | No | No | Yes | Yes | No | No | Yes | No |
| 6 | M | 38 | ADPKD | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 7 | M | 61 | HT + PRCC | Yes | No | No | No | No | Yes | No | Yes | Yes | No | Yes | Yes |
| 8 | F | 46 | Primary GN | No | Yes | No | No | No | Yes | No | Yes | No | No | No | No |
| 9 | M | 61 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 10 | M | 34 | Renal hypoplasia | Yes | No | No | No | No | No | Yes | Yes | Yes | No | Yes | Yes |
| 11 | M | 66 | Primary GN | Yes | No | No | No | Yes | Yes | No | Yes | No | No | No | No |
| 12 | M | 76 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 13 | M | 22 | Hypoplasia + VUR | No | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 14. | M | 25 | Primary GN | Yes | No | Yes | No | No | No | Yes | Yes | No | No | No | No |
| 15 | M | 68 | Primary GN | Yes | Yes | No | No | Yes | No | Yes | Yes | Yes | No | Yes | Yes |
| 16 | M | 52 | Primary GN | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 17 | F | 28 | Secondary GN (SLE) | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 18 | F | 50 | Nephronophthisis | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 19 | M | 65 | Secondary GN (ANCA) | Yes | No | Yes | No | No | No | Yes | Yes | No | No | No | No |
| 20 | M | 66 | HT | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 21 | F | 24 | Primary GN | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 22 | M | 28 | Primary GN | No | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 23 | F | 45 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 24 | M | 61 | Primary GN | No | No | No | Yes | No | No | Yes | Yes | No | No | Yes | No |
| 25 | F | 27 | aHUS | No | No | No | No | No | Yes | No | Yes | No | Yes | No | No |
| 26 | M | 76 | Nephronophthisis | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 27 | M | 29 | VUR | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 28 | M | 30 | Primary GN | No | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 29 | M | 48 | VUR | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 30 | M | 55 | Primary GN | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |

| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | M | 52 | Primary GN | Yes | No | No | Yes | No | Yes | No | Yes | No | No | No | No |
| 32 | M | 49 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 33 | M | 57 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 34 | M | 22 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 35 | M | 39 | HT | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 36 | M | 52 | Alport S. | Yes | No | No | Yes | No | Yes | No | Yes | No | No | No | No |
| 37 | M | 58 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 38 | F | 58 | Primary GN | Yes | No | No | Yes | No | Yes | No | Yes | No | Yes | No | No |
| 39 | F | 58 | Primary GN | Yes | No | No | No | No | No | Yes | Yes | No | No | No | No |
| 40 | M | 61 | ADPKD | Yes | No | No | No | No | Yes | No | Yes | No | No | No | No |
| 41 | M | 21 | Denis Drash S. | No | No | No | No | No | Yes | No | Yes | No | No | No | No |

Abbreviations: ADPKD, Autosomal dominant polycystic kidney disease; aHUS, atypical hemolytic uremic syndrome; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EVIg, intravenous Immunoglobulin; GN, glomerulonephritis; HT, hypertension; IL2R, interleukin-2 receptor; PEX, plasma exchange; PRCC, papillary renal cell carcinoma; PUV, posterior urethral valves; rATG, rabbit anti-thymocyte globulins; S., syndrome; SLE, systemic lupus erythematosus; VUR, vesicoureteral reflux.